AdAlta Ltd (ASX:1AD) CEO Tim Oldham tells Proactive the company has successfully dosed the first participants in its AD-214 Phase I extension study, marking the next milestone in the drug's development. AD-214 is being developed to target fibrotic diseases. AdAlta is on track to achieve interim results from the study before the end of 2023, providing a glimpse into the drug's potential. The final assessment visits are expected to be completed, and full results are anticipated to be available in the first quarter of 2024.
We extend our gratitude to the volunteers who are participating in this extension study, Oldham said.
Their involvement is essential in advancing a potential new therapy for sufferers of debilitating and incurable idiopathic pulmonary fibrosis and other fibrotic diseases.
AdAlta will be holding an online briefing discussing progress of the AD-214 Phase 1 extension study on Thursday 10 August at 10:30am (AEDT).
To participate in the live webcast, shareholders, investors and interested parties are invited to click on the link below to register:
+61 413 713 744
View source version on newsdirect.com: https://newsdirect.com/news/adalta-back-in-the-clinic-with-ad-214-997246697